Skip to content

Metastasis-driven first-line targeted therapy for HER2-positive gastric cancer : a real-world study

Metastasis-driven first-line targeted therapy for HER2-positive gastric cancer : a real-world study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600127307
Enrollment
Unknown
Registered
2026-06-29
Start date
2026-02-01
Completion date
Unknown
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

Patients with HER2-positive advanced gastric cancer:None

Sponsors

The first hospital of Shanxi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years, with no gender restriction; 2. Patients diagnosed and treated at the First Hospital of Shanxi Medical University; 3. Confirmed diagnosis of advanced gastric cancer; 4. Complete clinical data available, including tumor markers, liver function tests, complete blood count, etc; 5. Comprehensive pathological and clinical outcomes documented, including tumor location, degree of tumor differentiation, HER2 expression status, microsatellite status, progression-free survival (PFS), objective response rate (ORR), etc.

Exclusion criteria

Exclusion criteria: 1. Combined with other diagnosed malignant tumors; 2. Patients with incomplete clinical data.

Design outcomes

Primary

MeasureTime frame
Progression-Free Survival;Overall Survival;

Secondary

MeasureTime frame
Objective Response Rate;Disease Control Rate;

Countries

China

Contacts

Public ContactWang Yusheng

The first hospital of Shanxi Medical University

wangyusheng@sxmu.edu.cn+86 351 4639931

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 23, 2026